Haemato-oncologist @uhbtrust & Honorary Associate Clinical Professor UoB interested in lymphoma, CLL & Cellular therapies. Firm believer in patient choice
Birmingham
Joined December 2013
- Tweets7.2K
- Following624
- Followers521
- Likes1.3K
Shankara Paneesha retweeted
Profound sorry that my mentor, friend, and colleague, the legend Bob Kyle passed away. His contributions to patients, medicine, myeloma, @IMFmyeloma @MayoClinic myeloma group, and the institution are monumental. A role model who will be remembered for his integrity and commitment to patients. I owe my career to him. He leaves behind a legacy of experts at Mayo Clinic as well as world over who were influenced greatly by him.
See thread for links to a video an article on him that I wrote for @MayoProceedings
Post your memories below.
NICE Expands First-Line Options for Two Blood Cancers Great news for our patients medscape.com/viewarticle/nic…
facebook.com/share/v/1PhKHGe… Another week to go!
@tonyiommi thanks for all your support
Indeed great CPD on myeloid conditions for someone who doesn’t routinely do myeloid on call
What a fantastic day learning about practice changing updates from Great speakers. Thank you @HaemOnc, @dr_de_Lavallade and Dr Priyanka Mehta for myeloid updates and @DrFSeymour and Dr Dean Smith for myeloma updates chaired by @hannahvgiles
Great debate @UKCHART annual Education Day
MRD adapted treatment discontinuation in myeloma
@profBigG @profghjackson
Great news for our patients
BeOne Medicines’ BEQALZI™ (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma - businesswire.com/news/home/2…
Exciting trial!
Wish it was a multi national study
Whether platform trial with pick the winner may be better for RT
Excited to kick-off the @SWOG S2504 trial which is the first randomized trial for Richter Transformation (RT) in the US:
Pirtobrutinib with RCHOP vs. RCHOP is TN RT
Asking all #CLL and #lymphoma experts to participate and spread the word.
Special thanks to @DebbieMStephens the study co-chair and @DanilovLab the TM chair. Thanks to @NCIMedia and @EliLillyandCo
@CllSociety @lymphoma @SOU_LnL_Fund
@fredhutch @cityofhope @UNC_Lineberger
Shankara Paneesha retweeted
Conferences are great for CPD- much of what we hear isn’t immediately usable in our system.
Let experts distil it down😀
👇Join the brilliant @Paneeshas @VidhyaMurthy1 & others
I learnt a lot from both
Maybe they teach you a thing or two :)
#medicine #hematology #medtwitter
Excellent opportunity to catch up with the updates from summer congress with national haematology speakers
Join us for the Summer Congress Insights meeting in Birmingham on Friday 26th June. Updates from ASCO and EHA by leading clinicians in the field. A fantastic opportunity for networking too. For more details: insightmeetings.co.uk/summer…
To register: insightmeetings.co.uk/regist…
Great news for our patients
Finally! A NICE approved bispecific in released / refractory follicular lymphoma. Great news. #lymsm
Great work from Bham team
Vaishali and Sridhar great leadership and performance
Fantastic talk today by Vaishali Dulobdas at #ASH2025 on effect of immune parameters and IgRT on post CD19 CAR T outcomes. #lymsm #uhbtrust #nickduncan31 @Capt__Kirkwood @immunologydoc @lymphomule @CCHBham @Paneeshas @lymphomahub @DrLindsayG
Important data so now we can make individual treatment decisions based on patient choice and other considerations
Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia | New England Journal of Medicine nejm.org/doi/full/10.1056/NE…
Another great choice for our patients
Pirtobrutinib is now approved for pts with #CLL after cBTKi.
Pirtobrutinib can now be used in second line, potentially.
Big #ASH25 for pirtobrutinib!
fda.gov/drugs/resources-info…
Another great choice for our patients
Zanubrutinib approved for relapsed #MCL by @NICEComms #lymsm
Final draft guidance avaliable
nice.org.uk/guidance/indevel…
Measurable Residual Disease–Guided Therapy for Chronic Lymphocytic Leukemia | NEJM nejm.org/doi/full/10.1056/NE…
Great work from UK Team! Undetectable MRD and extended progression-free survival were more common with ibrutinib–venetoclax than with ibrutinib alone
Shankara Paneesha retweeted
➡️➡️Big CLL news!
Munir et al
OS and PFS adv for MRD driven I&V over ibrutinib in 1L #CLL #EHA2025
Congrats to all FLAIR trial 🇬🇧group
Measurable Residual Disease–Guided Therapy for Chronic Lymphocytic Leukemia | New England Journal of Medicine nejm.org/doi/full/10.1056/NE…
